GNFT

Nitazoxanide

NASH-induced significant or severe fibrosis

Stage (next event)

Expected Date

Phase 2

TBD

Catalyst Info & Data Links

TITLE: Nitazoxanide for NASH-induced significant or severe fibrosis 

  • NCT03656068: An Evaluation of the Safety and Efficacy of NTZ on Collagen Turnover in NASH Patients With Fibrosis


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 Readout


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR? 

  • TBD


PRIOR DATA

PRESS RELEASES


Mechanism of Action

MECHANISM OF ACTION

  • Our research program designed to discover novel anti-fibrotic molecules uses a phenotypic screening approach5 combined with the use of a compound library composed of FDA-approved drugs. In our model, we evaluated the compounds for their capacity to interfere with the activation of quiescent hepatic stellate cells into myofibroblasts, which are the major fibrogenic cell type in the liver.

  • After screening the pharmacopea, and investigating the drug candidate profiles in medical literature, we identified nitazoxanide, or NTZ; currently commercialized and prescribed in the United States and several other countries as an anti-parasitic; as a potent anti-fibrotic agent that we believe can be repurposed for the treatment of fibrosis.

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon